Click here to see full image, courtesy of Joost M. Bakker, PhD., Sr. Scientific Writer & Graphic Designer, Genmab BV, Utrecht, The Netherlands.

Links

Mission Statement

Editorial Board

Submission Guidelines

Online Submission

Contact mAbs

mAbs 101 - What are mAbs?

In January of 2009 mAbs, the first international peer-reviewed journal of its kind to focus exclusively on monoclonal antibodies, will be launched. We believe that this is an excellent time to start the journal because of the increasing focus on mAbs as therapeutics. There has been a rapid increase in mAb R&D by academia, government and industry located world wide. Novel mAb therapeutics are entering clinical study by commercial sponsors at a record pace (Figure 1) that is predicted to continue well into the future. MAbs have proven successful in the clinic, with 21 therapeutic products approved in the US as of 2007 (Table 1). In addition, a global market has emerged for the products - several novel mAbs not yet available in the US or EU are now approved in China.